Education
About Us
Working with TipRanks
Follow Us
Livzon Pharmaceutical Group Inc Class H (HK:1513)
:1513
RESEARCH TOOLSreports
Total Valuation
Livzon Pharmaceutical Group has a market cap or net worth of $30.26B. The enterprise value is HK$18.62B.
Market Cap$30.26B
Enterprise ValueHK$18.62B
Share Statistics
Livzon Pharmaceutical Group has 307,052,430 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding307,052,430
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Livzon Pharmaceutical Group’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 12.11%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)12.11%
Return on Capital Employed (ROCE)0.17
Revenue Per Employee1.30M
Profits Per Employee254.16K
Employee Count9,067
Asset Turnover0.48
Inventory Turnover2.04
Valuation Ratios
The current PE Ratio of Livzon Pharmaceutical Group is 11.55. Livzon Pharmaceutical Group’s PEG ratio is 1.73.
PE Ratio11.55
PS Ratio0.00
PB Ratio1.72
Price to Fair Value1.72
Price to FCF9.88
Price to Operating Cash Flow7.99
PEG Ratio1.73
Income Statement
In the last 12 months, Livzon Pharmaceutical Group had revenue of 11.81B and earned 2.06B in profits. Earnings per share was 2.24.
Revenue11.81B
Gross Profit7.73B
Operating Income2.84B
Pretax Income2.81B
Net Income2.06B
EBITDA3.47B
Earnings Per Share (EPS)2.24
Cash Flow
In the last 12 months, operating cash flow was 605.78M and capital expenditures 0.00, giving a free cash flow of 1.58B billion.
Operating Cash Flow605.78M
Free Cash Flow1.58B
Free Cash Flow per Share5.15
Dividends & Yields
Livzon Pharmaceutical Group pays an annual dividend of HK$1.169, resulting in a dividend yield of 5.66%
Dividend Per ShareHK$1.169
Dividend Yield5.66%
Payout Ratio60.82%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.62
52-Week Price Change-0.13%
50-Day Moving Average26.24
200-Day Moving Average26.11
Relative Strength Index (RSI)45.45
Average Volume (3m)1.09M
Important Dates
Livzon Pharmaceutical Group upcoming earnings date is Aug 21, 2025, TBA Not Confirmed.
Last Earnings DateApr 24, 2025
Next Earnings DateAug 21, 2025
Ex-Dividend DateJun 13, 2025
Financial Position
Livzon Pharmaceutical Group as a current ratio of 2.15, with Debt / Equity ratio of 26.63%
Current Ratio2.15
Quick Ratio1.89
Debt to Market Cap0.16
Net Debt to EBITDA-1.99
Interest Coverage Ratio32.10
Taxes
In the past 12 months, Livzon Pharmaceutical Group has paid 501.66M in taxes.
Income Tax501.66M
Effective Tax Rate0.18
Enterprise Valuation
Livzon Pharmaceutical Group EV to EBITDA ratio is 4.87, with an EV/FCF ratio of 7.02.
EV to Sales1.43
EV to EBITDA4.87
EV to Free Cash Flow7.02
EV to Operating Cash Flow5.68
Balance Sheet
Livzon Pharmaceutical Group has $10.90B in cash and marketable securities with ¥3.77B in debt, giving a net cash position of -$7.13B billion.
Cash & Marketable Securities$10.90B
Total Debt¥3.77B
Net Cash-$7.13B
Net Cash Per Share-$23.21
Tangible Book Value Per Share$15.39
Margins
Gross margin is 65.53%, with operating margin of 24.08%, and net profit margin of 17.45%.
Gross Margin65.53%
Operating Margin24.08%
Pretax Margin23.76%
Net Profit Margin17.45%
EBITDA Margin29.38%
EBIT Margin24.51%
Analyst Forecast
The average price target for Livzon Pharmaceutical Group is $22.98, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target$22.98
Price Target Upside-11.29% Downside
Analyst ConsensusModerate Sell
Analyst Count0
Revenue Growth Forecast-5.37%
EPS Growth Forecast6.28%